menu
    • menu

    Company profile for Palleon Pharmaceuticals

    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-12-22

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    HTL Biotechnology is a French biotech & a global leader in the responsible development & production of pharma-grade biopolymers.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Palleon is advancing a suite of platform technologies that uniquely enable drug development in glyco-immunology. Palleon’s EAGLE platform employs a novel strategy of enzymatic sialoglycan degradation which overcomes intractable biological redundancy and enables a uniquely pan-immune anti-tumor response to address patient populations who are resistant to first generation immuno-oncology drugs. Palleon’s HYDRA translational ...
    Palleon is advancing a suite of platform technologies that uniquely enable drug development in glyco-immunology. Palleon’s EAGLE platform employs a novel strategy of enzymatic sialoglycan degradation which overcomes intractable biological redundancy and enables a uniquely pan-immune anti-tumor response to address patient populations who are resistant to first generation immuno-oncology drugs. Palleon’s HYDRA translational platform characterizes cancer patients by their tumor surface glycan profile to identify populations that have tumors that utilize this mechanism.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Palleon PharmaceuticalsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    266 Second Avenue Waltham MA 02451
    Telephone
    Telephone
    (857) 285-5900
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://palleonpharma.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/palleon-pharmaceuticals
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/Palleon_Pharma

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    DCAT Week

    DCAT Week

    Not Confirmed

    envelop Contact Supplier

    DCAT Week

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Palleon Pharma Showcases HLX79/E-602 For Autoimmune Disease
    Palleon Pharma Showcases HLX79/E-602 For Autoimmune Disease

    22 Oct 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251022805053/en/Palleon-Pharmaceuticals-to-Present-on-Development-of-HLX79E-602-in-Autoimmune-Disease-at-the-American-College-of-Rheumatology-Convergence-Annual-Meeting-and-the-American-Society-of-Nephrology-Kidney-Week

    BUSINESSWIRE
    22 Oct 2025
    Share Share
    1st Patient Dosed in Palleon's Ph 2 Trial for Glomerulonephritis
    1st Patient Dosed in Palleon's Ph 2 Trial for Glomerulonephritis

    07 Aug 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250807852328/en/Palleon-Pharmaceuticals-Announces-First-Patient-Dosed-in-Phase-2-Clinical-Trial-of-E-602-HLX79-a-Potential-First-In-Class-Treatment-for-Active-Glomerulonephritis

    BUSINESSWIRE
    07 Aug 2025
    Share Share
    Palleon Pharmaceuticals: NMPA IND Clearance for E-602 Phase 2 Trial
    Palleon Pharmaceuticals: NMPA IND Clearance for E-602 Phase 2 Trial

    02 Apr 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250402600282/en/Palleon-Pharmaceuticals-Announces-NMPA-IND-Clearance-to-Proceed-with-Phase-2-Clinical-Trial-of-E-602-HLX79-a-First-In-Class-Treatment-for-Autoimmune-Diseases

    BUSINESSWIRE
    02 Apr 2025
    Share Share
    Palleon & Henlius Partner to Advance Glycan for Autoimmune Diseases
    Palleon & Henlius Partner to Advance Glycan for Autoimmune Diseases

    19 Dec 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241219653670/en

    BUSINESSWIRE
    19 Dec 2024
    Share Share
    Palleon Pharma GLIMMER-01 E-602 + Cemiplimab Data at SITC
    Palleon Pharma GLIMMER-01 E-602 + Cemiplimab Data at SITC

    08 Nov 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241108273263/en

    BUSINESSWIRE
    08 Nov 2024
    Share Share
    Palleon to Present New Findings on Colorectal Tumor Microenvironment
    Palleon to Present New Findings on Colorectal Tumor Microenvironment

    31 Oct 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20231030129146/en

    BUSINESSWIRE
    31 Oct 2023
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search